New ADHD drug shows promise in small trial
NCT ID NCT01939353
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested a new drug called EB-1020 SR (centanafadine) in 45 adult men with ADHD. The goal was to see if it could reduce symptoms like inattention and hyperactivity. Participants took the drug or a placebo for a few weeks, and researchers measured changes using a standard ADHD rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EB-1020 SR (centanafadine sustained release)
- What this could lead to
- If successful, this could point toward a new medication option for adults with ADHD to help reduce symptoms like inattention and hyperactivity.
- What could go wrong
- This is an early Phase 2 trial with only 45 men, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ADHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Bradenton, Florida, 34201, United States
-
Study site
Maitland, Florida, 32751, United States
-
Study site
Las Vegas, Nevada, 89128, United States